These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28683295)

  • 1. Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?
    Claus SP
    Cell Metab; 2017 Jul; 26(1):6-7. PubMed ID: 28683295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.
    Grasset E; Puel A; Charpentier J; Collet X; Christensen JE; Tercé F; Burcelin R
    Cell Metab; 2017 May; 25(5):1075-1090.e5. PubMed ID: 28467926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minireview: update on incretin biology: focus on glucagon-like peptide-1.
    Brubaker PL
    Endocrinology; 2010 May; 151(5):1984-9. PubMed ID: 20305008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 and diabetes 2012.
    Monami M; Di Pasquale G; Rowzee A; Rotella CM; Mannucci E
    Exp Diabetes Res; 2012; 2012():768760. PubMed ID: 23431286
    [No Abstract]   [Full Text] [Related]  

  • 6. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.
    Zinman B
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():1-3. PubMed ID: 19878255
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucagon-like peptide-1 and its cardiovascular effects.
    Heo KS; Fujiwara K; Abe J
    Curr Atheroscler Rep; 2012 Oct; 14(5):422-8. PubMed ID: 22878937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of glucagon secretion by incretins.
    Holst JJ; Christensen M; Lund A; de Heer J; Svendsen B; Kielgast U; Knop FK
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():89-94. PubMed ID: 21824261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
    Rochoń J; Kalinowski P; Szymanek-Majchrzak K; Grąt M
    World J Gastroenterol; 2024 Jun; 30(23):2964-2980. PubMed ID: 38946874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids.
    Yao Y; Yan L; Chen H; Wu N; Wang W; Wang D
    Phytomedicine; 2020 Oct; 77():153268. PubMed ID: 32663709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.